MAIA Biotechnology Inc
For the period ended Dec 31, 2023. Filed Mar 21, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 21, 2024
MAIA$1.05-3.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
Consolidated Statements of Cash Flows
| Years Ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Cash flows from operating activities: | ||
| Net loss | $(19,772,905) | $(15,769,279) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation | 3,089,304 | 2,319,427 |
| Issuance of ratchet shares | — | 1,099,360 |
| Consulting expense for restricted shares issued | 731,661 | — |
| Change in fair value of warrant liability | (205,130) | (98,394) |
| Change in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | 285,831 | (505,233) |
| Australia research and development incentives receivable | 158,405 | (269,395) |
| Other assets | — | 322 |
| Accounts payable | 471,897 | 211,346 |
| Accrued expenses | 2,169,921 | 915,742 |
| Net cash used in operating activities | (13,071,016) | (12,096,104) |
| Cash flows from financing activities: | ||
| Proceeds from issuance of common stock, net of transaction costs | — | 2,473,560 |
| Deferred offering costs | — | 440,379 |
| Proceeds from exercise of stock options | 1,432 | 84,000 |
| Proceeds from exercise of warrants | — | 385,400 |
| Proceeds from sale of common stock in initial public offering | — | 11,500,000 |
| Payment of initial public offering transaction costs | — | (2,406,170) |
| Proceeds from sale of common stock in follow-on offering | 5,749,875 | — |
| Proceeds from direct offering | 4,000,001 | — |
| Proceeds from At-The-Market offering | 1,667,084 | — |
| Payment of 2023 offering transactions costs | (2,147,491) | — |
| Net cash provided by financing activities | 9,270,901 | 12,477,169 |
| Net effect of foreign currency exchange on cash | (117) | (4,430) |
| Net decrease in cash | (3,800,232) | 376,635 |
| Cash at beginning of period | 10,950,927 | 10,574,292 |
| Cash at end of period | $7,150,695 | $10,950,927 |
| Supplemental disclosure of cash flow information: | ||
| Previously paid issuance costs in connection with the initial public offering | — | 651,582 |
| Warrants issued to underwriters in connection with the initial public offering | — | 343,735 |
| Options issued for accrued bonus | $974,224 | — |
| Warrants issued to underwriters in connection with the follow-on offering | $241,109 | — |
| Warrants issued in connection with the At-The-Market offering | $84,251 | — |
| Warrants issued in connection with the direct offering | 1,903,915 | — |
| Warrants issued to underwriters in connection with the direct offering | $123,811 | — |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.